Clinical Trials Logo

Dasatinib clinical trials

View clinical trials related to Dasatinib.

Filter by:
  • None
  • Page 1

NCT ID: NCT05523661 Recruiting - Dasatinib Clinical Trials

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

Start date: March 1, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the safety and efficacy of Dasatinib plus CD19/CD22 Bispecific CAR-T for the treatment of elderly Ph-positive lymphoblastic leukemia. Newly diagnosed Ph-positive patients will be given Dasatinib plus VP chemotherapy for induction treatment,if a hematologic complete remission was observed then a lymphocyte collection will be administrated to patients. Then chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells

NCT ID: NCT04155411 Recruiting - Clinical trials for Chronic Myeloid Leukemia

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Start date: December 1, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of dasatinib 70 mg once daily as first line therapy in patients with early chronic phase (CP) chronic myeloid leukemia (CML).

NCT ID: NCT04115059 Terminated - Clinical trials for Waldenstrom Macroglobulinemia

Dasatinib In Waldenström Macroglobulinemia

Start date: November 4, 2019
Phase: Phase 1
Study type: Interventional

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations